Get the Stockscreener App
0.7062
5.46%
-0.0408
After Hours:
.73
0.0238
+3.37%
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Stock Plummets to 52-Week Low of $0.78 By Investing.com - Investing.com Nigeria
Jaguar Health Stock Plummets to 52-Week Low of $0.78 - Investing.com
Form DEF 14A Jaguar Health, Inc. For: Mar 13 - StreetInsider.com
Jaguar Health extends debt maturity to 2026 By Investing.com - Investing.com South Africa
Jaguar Health extends debt maturity to 2026 - Investing.com India
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease StudyShort Bowel Syndrome with Intestinal Failure (SBS-IF) - Yahoo Finance
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges - MSN
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern - ACCESS Newswire
Jaguar Health extends collaboration with Streeterville - TipRanks
Jaguar Health advances cholera treatment, eyes FDA voucher - Investing.com India
Jaguar Health extends collaboration with Streeterville to develop P-300 - TipRanks
Jaguar Health advances cholera treatment, eyes FDA voucher By Investing.com - Investing.com Nigeria
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 - ACCESS Newswire
Jaguar Health's Cholera Drug Could Unlock $350M FDA Voucher as WHO Declares Emergency - StockTitan
Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website - ACCESS Newswire
Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - WSIL TV
Exclusive Investor Presentation: Jaguar Health CEO Reveals Strategic Roadmap and Growth Catalysts - StockTitan
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote - ACCESS Newswire
Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020 - ACCESS Newswire
Jaguar Health Provides Updates Regarding Company Capitalization Strategy - ACCESS Newswire
Jaguar Health to Present at Biotech Showcase 2019 in San Francisco - ACCESS Newswire
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference - Huntsville Item
Breakthrough Plant-Based Drug Takes Aim at $38B ADHD & Schizophrenia Markets - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30% - Simply Wall St
Jaguar Health extends loan maturity, issues stock for royalty interest reduction - MSN
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Jaguar Health announces first SBS-IF patient dosed in IIT trial of crofelemer - TipRanks
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 - Yahoo Finance
Rare Disease Breakthrough: First SBS-IF Patient Dosed in Groundbreaking Pediatric Trial - StockTitan
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO - ACCESS Newswire
This Drug Could Fix The Biggest Problem With Ozempic and Wegovy - StockTitan
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones - ACCESS Newswire
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs - ACCESS Newswire
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 - ACCESS Newswire
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning - ACCESS Newswire
Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - ACCESS Newswire
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference - ACCESS Newswire
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - ACCESS Newswire
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - ACCESS Newswire
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs - ACCESS Newswire
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - ACCESS Newswire
Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ COVID-19 Recovery Patients in Europe - ACCESS Newswire
Jaguar Health Appoints Carol Lizak Chief Accounting Officer - ACCESS Newswire
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise - ACCESS Newswire
Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award - ACCESS Newswire
Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher - ACCESS Newswire
Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer" - ACCESS Newswire
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea - ACCESS Newswire
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market - ACCESS Newswire
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care - ACCESS Newswire
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet - ACCESS Newswire
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care - ACCESS Newswire
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency - ACCESS Newswire
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) - ACCESS Newswire
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - ACCESS Newswire
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - ACCESS Newswire
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. - ACCESS Newswire
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patien - ACCESS Newswire
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):